Eli Lilly LLY
-
Lilly CEO recovering after repair to aorta
May 14 (Reuters) - John Lechleiter, the longtime chief executive of Eli Lilly and Co, is recovering from successful surgery to repair a dilated aorta, the U.S. drugmaker said on Tuesday.
-
New Morningstar Analyst Report - Amgen
… drugs such as Novartis' Reclast and cheaper generic bisphosphonates; Vectibix competes with Roche's RHHBY Avastin and Eli Lilly LLY and Bristol-Myers Squibb's BMY Erbitux. If Amgen's late-stage pipeline disappoints, the company could be …
-
UPDATE 1- Eli Lilly lymphoma drug fails in late-stage trial
May 10 (Reuters) - Eli Lilly and Co said it will end development of an experimental cancer drug after it failed in a late-stage trial to delay a worsening of symptoms in patients with lymphoma.
-
Eli Lilly's lymphoma drug fails in late-stage trial
May 10 (Reuters) - Eli Lilly and Co said it will stop developing its experimental cancer drug after a late-stage trial failed to show a statistically significant increase in patients' disease-free survival.
-
New Morningstar Analyst Report for Becton, Dickinson and Company
… may incur substantial monetary damages.Becton's diabetes sales may decline if large producers of insulin, such as Eli Lilly and Sanofi-Aventis, choose to prepackage insulin with internally manufactured delivery devices.Becton's raw-material …
-
New Morningstar Analyst Report - Eli Lilly & Company
… to drive significant strategy changes at the company. Eli Lilly is a pharmaceutical company with a focus on neuroscience ..... approvals, patent challenges, and liability lawsuits. Eli Lilly 's innovative culture and strong financial commitment …
-
New Morningstar Analyst Report for Sanofi-Aventis ADR
… of sales come from Lantus, the company faces additional product specific risks from upcoming competitive launches from Eli Lilly and Novo Nordisk. Sanofi's wide lineup of branded drugs and vaccines and a robust pipeline create strong cash flows …
-
New Morningstar Analyst Report for Dendreon Corporation
… meaningful turnaround at Dendreon before assuming future operational improvements. Johnson oversaw the sale of ImClone to Eli Lilly in 2008, and his appointment could reinvigorate takeover speculation for Dendreon, which has historically scored near …
-
3 Bio Companies Facing The Patent Cliff
… This article looks at three major biotech companies facing significant revenue loss in 2013 due to patent expiration - Eli Lilly & Co ( LLY ), Biogen Idec Inc . ( BIIB ) and Johnson & Johnson ( JNJ ). The patent cliff threat Between now and 2018 …
-
Eli Lilly (LLY) declares $0.49/share quarterly dividend, in line with previous. Forward yield 3.60%. For shareholders of record May 16. Payable June 10. Ex-div date May 14. (PR)
Eli Lilly ( LLY ) declares $0.49/share quarterly dividend, in line with previous. Forward yield 3.60%. For shareholders of record May 16. Payable June 10. Ex-div date May 14. ( PR ) Post your comment!